Publications by authors named "K Ristow"
Article Synopsis
- Mantle cell lymphoma (MCL) varies in prognosis, with blastoid and pleomorphic variants generally having poorer outcomes.
- A study involving 1029 MCL patients over 15 years focused on the characteristics and survival rates of those with these variants, finding a median progression-free survival (PFS) of 38 months and overall survival (OS) of 68 months.
- Key factors influencing PFS included receiving autologous hematopoietic transplantation (auto-HCT) and MCL International Prognostic Index (MIPI) scores; however, auto-HCT did not improve OS, indicating its benefits are more related to managing the disease's progression rather than overall survival.
The (WHO 2017) included updated criteria for diagnosis and classification of post-transplant lymphoproliferative disorders (PTLDs). This study evaluated the clinicopathologic spectrum using WHO 2017 criteria and adult PTLD patients' outcomes over 30 years between 1987 and 2017 at Mayo Clinic (Rochester, MN). Patients were retrospectively reviewed for clinical features, outcomes, and diagnostic pathology material and classified based on WHO 2017 criteria.
View Article and Find Full Text PDFNeurolymphomatosis (NL) is a rare manifestation of lymphoma, with limited evidence for optimal management. The largest patient series, 50 cases of lymphoma and leukemia, was published in 2010 with limited rituximab exposure. This study aims to evaluate the clinical presentation, diagnostic testing, and outcomes of NL in the rituximab era.
View Article and Find Full Text PDFPrimary gastrointestinal (GI) mantle cell lymphoma (MCL) is rare and the optimal management is unknown. We reviewed 800 newly diagnosed MCL cases and found 22 primary (2.8%) and 79 (9.
View Article and Find Full Text PDF